The deal would give the American pharmaceutical giant access to Anacor's flagship eczema treatment gel Crisaborole.
But the move might not hamper the death penalty. Some states allow hangings if lethal-injection drugs aren’t available.
The American pharmaceutical giant’s first-quarter revenue, boosted by its cancer drug sales and acquisition of Hospira, came in at $13 billion.
Pharmaceutical companies announced deals worth $40 billion this week, but not everyone is convinced they’re good for business.
The French pharmaceutical multinational made an offer for the U.S. drugmaker in an effort to expand its cancer-treatment business.
In some small countries, the profits reported by American corporations are larger than the entire gross domestic product.
Parliament should probe the nation's tax practices and consider direct rule of territories that serve as tax havens, Labour leader Jeremy Corbyn says.
The Treasury’s new rules on inversion-type transactions torpedoed the pharmaceutical deal, but a tough debate about corporate tax reform remains.
The $160 billion deal, announced last year, was canceled Wednesday after the U.S. Department of Treasury passed a new law to curb tax inversion deals.
Shares of the media giant were a major drag on the Dow on Tuesday after the company said a veteran executive will step down.
Under the new rules, there will be a three-year limit on foreign companies bulking up on U.S. assets to avoid ownership requirements for a later inversions deal.
According to Americans for Tax Fairness, the deal would allow the U.S. pharma giant to "permanently dodge" taxes owed on about $148 billion in overseas profits.
The most important economic variable of 2016 might be whether American consumers are strong enough to withstand the cold winds blowing in from abroad.
Developing a vaccine against the mosquito-borne virus could take years, researchers have said.
The New York-based pharmaceutical company reported a better-than-expected 7 percent rise in quarterly revenue Tuesday.
The healthcare conglomerate said Tuesday the restructuring would affect its orthopedics, surgery and cardiovascular businesses.
The company raised prices, by as much as 20 percent for some drugs, on Jan. 1.
The past year saw deals worth nearly $4.3 trillion — significantly above the previous peak, before the financial crisis, according to a Thursday report.
The deals, which include an upfront payment of $350 million, will help the British drugmaker compete with its American rival Gilead Sciences.
The British drugmaker has shown interest in Acerta's anti cancer treatments, particularly an experimental drug called Acalabrutinib.
Global M&A activity rose as companies looked for tax havens and took advantage of cheap interest rates, the Wall Street Journal reported, citing a research report.
Japan stocks are little changed after a holiday while Australian shares fell, dragged down by falling metal prices.